{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T03:17:18Z","timestamp":1774927038787,"version":"3.50.1"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T00:00:00Z","timestamp":1540252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Oral switch to linezolid is a promising alternative to standard parenteral therapy (SPT) in Staphylococcus aureus bacteremia (SAB).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a prospective cohort study of all adult cases of SAB between 2013 and 2017 in a Spanish university hospital. We compared the ef\ufb01cacy, safety, and length of hospital stay of patients receiving SPT and those where SPT was switched to oral linezolid between days 3 and 9 of treatment until completion. We excluded complicated SAB and osteoarticular infections. A k-nearest neighbor algorithm was used for propensity score matching with a 2:1 ratio.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>After propensity score matching, we included 45 patients from the linezolid group and 90 patients from the SPT group. Leading SAB sources were catheter related (49.6%), unknown origin (20.0%), and skin and soft tissue (17.0%). We observed no difference in 90-day relapse between the linezolid group and the SPT group (2.2% vs 4.4% respectively; P = .87). No statistically significant difference was observed in 30-day all-cause mortality between the linezolid group and the SPT group (2.2% vs 13.3%; P = .08). The median length of hospital stay after onset was 8 days in the linezolid group and 19 days in the SPT group (P &lt; .01). No drug-related events leading to discontinuation were noted in the linezolid group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Treatment of SAB in selected low-risk patients with an oral switch to linezolid between days 3 and 9 of treatment until completion yielded similar clinical outcomes as SPT, allowing earlier discharge from the hospital.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciy916","type":"journal-article","created":{"date-parts":[[2018,10,21]],"date-time":"2018-10-21T15:06:28Z","timestamp":1540134388000},"page":"381-387","source":"Crossref","is-referenced-by-count":67,"title":["Early Oral Switch to Linezolid for Low-risk Patients With Staphylococcus aureus Bloodstream Infections: A Propensity-matched Cohort Study"],"prefix":"10.1093","volume":"69","author":[{"given":"Rein","family":"Willekens","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mireia","family":"Puig-Asensio","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Ruiz-Camps","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria N","family":"Larrosa","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan J","family":"Gonz\u00e1lez-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolors","family":"Rodr\u00edguez-Pardo","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"Fern\u00e1ndez-Hidalgo","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carles","family":"Pigrau","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benito","family":"Almirante","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,10,23]]},"reference":[{"key":"2019071803461665300_CIT0001","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1469-0691.2012.03903.x","article-title":"The changing epidemiology of Staphylococcus aureus bloodstream infection: a multinational population-based surveillance study","volume":"19","author":"Laupland","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"2019071803461665300_CIT0002","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1093\/cid\/cit499","article-title":"Impact of an evidence-based bundle intervention in the quality-of-care management and outcome of Staphylococcus aureus bacteremia","volume":"57","author":"L\u00f3pez-Cort\u00e9s","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2019071803461665300_CIT0003","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/QCO.0b013e32833bcc8a","article-title":"Management of Staphylococcus aureus bacteremia and endocarditis: progresses and challenges","volume":"23","author":"Kern","year":"2010","journal-title":"Curr Opin Infect Dis"},{"key":"2019071803461665300_CIT0004","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1001\/archinte.163.17.2066","article-title":"Clinical identifiers of complicated Staphylococcus aureus bacteremia","volume":"163","author":"Fowler","year":"2003","journal-title":"Arch Intern Med"},{"key":"2019071803461665300_CIT0005","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1128\/CMR.00134-14","article-title":"Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management","volume":"28","author":"Tong","year":"2015","journal-title":"Clin Microbiol Rev"},{"key":"2019071803461665300_CIT0006","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1128\/AAC.01021-12","article-title":"Treatment duration for uncomplicated Staphylococcus aureus bacteremia to prevent relapse: analysis of a prospective observational cohort study","volume":"57","author":"Chong","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071803461665300_CIT0007","doi-asserted-by":"crossref","first-page":"304","DOI":"10.7326\/0003-4819-119-4-199308150-00010","article-title":"Short-course therapy of catheter-related Staphylococcus aureus bacteremia: a meta-analysis","volume":"119","author":"Jernigan","year":"1993","journal-title":"Ann Intern Med"},{"key":"2019071803461665300_CIT0008","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/jama.2014.9743","article-title":"Clinical management of Staphylococcus aureus bacteremia: a review","volume":"312","author":"Holland","year":"2014","journal-title":"JAMA"},{"key":"2019071803461665300_CIT0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/cir320","article-title":"Use of a simple criteria set for guiding echocardiography in nosocomial Staphylococcus aureus bacteremia","volume":"53","author":"Kaasch","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2019071803461665300_CIT0010","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1086\/595686","article-title":"Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study","volume":"48","author":"Wilcox","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2019071803461665300_CIT0011","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/jac\/dki355","article-title":"Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies","volume":"56","author":"Shorr","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"2019071803461665300_CIT0012","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/cid\/cir895","article-title":"Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study","volume":"54","author":"Wunderink","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2019071803461665300_CIT0013","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/jac\/dkh088","article-title":"Linezolid compared with teicoplanin for the treatment of suspected or proven gram-positive infections","volume":"53","author":"Wilcox","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"2019071803461665300_CIT0014","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/340353","article-title":"Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections","volume":"34","author":"Stevens","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2019071803461665300_CIT0015","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1086\/345744","article-title":"Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program","volume":"36","author":"Birmingham","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2019071803461665300_CIT0016","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1469-0691.2006.01585.x","article-title":"Linezolid therapy for infective endocarditis","volume":"13","author":"Mu\u00f1oz","year":"2007","journal-title":"Clin Microbiol Infect"},{"key":"2019071803461665300_CIT0017","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1086\/427806","article-title":"Risk factors for hematogenous complications of intravascular catheter-associated Staphylococcus aureus bacteremia","volume":"40","author":"Fowler","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2019071803461665300_CIT0018","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/00365540500372846","article-title":"Persistence in Staphylococcus aureus bacteremia: incidence, characteristics of patients and outcome","volume":"38","author":"Khatib","year":"2006","journal-title":"Scand J Infect Dis"},{"key":"2019071803461665300_CIT0019","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1086\/514686","article-title":"Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients","volume":"27","author":"Fowler","year":"1998","journal-title":"Clin Infect Dis"},{"key":"2019071803461665300_CIT0020","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1086\/377540","article-title":"Outcome of Staphylococcus aureus bacteremia in patients with eradicable foci versus noneradicable foci","volume":"37","author":"Kim","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2019071803461665300_CIT0021","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s150100050065","article-title":"Metastatic complications of Staphylococcus aureus septicemia. To seek is to find","volume":"28","author":"Ringberg","year":"2000","journal-title":"Infection"},{"key":"2019071803461665300_CIT0022","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1128\/CMR.05022-11","article-title":"Predictors of mortality in Staphylococcus aureus bacteremia","volume":"25","author":"van Hal","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"2019071803461665300_CIT0023","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2019071803461665300_CIT0024","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1086\/502156","article-title":"Role of comorbidity in mortality related to Staphylococcus aureus bacteremia: a prospective study using the Charlson weighted index of comorbidity","volume":"24","author":"Lesens","year":"2003","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2019071803461665300_CIT0025","doi-asserted-by":"crossref","first-page":"791","DOI":"10.7326\/0003-4819-137-10-200211190-00007","article-title":"Health care\u2013associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections","volume":"137","author":"Friedman","year":"2002","journal-title":"Ann Intern Med"},{"key":"2019071803461665300_CIT0026","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"2019071803461665300_CIT0027","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/0196-6553(88)90053-3","article-title":"CDC definitions for nosocomial infections, 1988","volume":"16","author":"Garner","year":"1988","journal-title":"Am J Infect Control"},{"key":"2019071803461665300_CIT0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/599376","article-title":"Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America","volume":"49","author":"Mermel","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2019071803461665300_CIT0029","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/cid\/civ308","article-title":"Comparative effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections among 122 hospitals","volume":"61","author":"McDanel","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2019071803461665300_CIT0030","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1128\/JCM.00262-14","article-title":"Bacterial whole-genome sequencing revisited: portable, scalable, and standardized analysis for typing and detection of virulence and antibiotic resistance genes","volume":"52","author":"Leopold","year":"2014","journal-title":"J Clin Microbiol"},{"key":"2019071803461665300_CIT0031","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/cid\/ciw828","article-title":"Gram-positive bacterial infections: research priorities, accomplishments, and future directions of the Antibacterial Resistance Leadership Group","volume":"64","author":"Doernberg","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2019071803461665300_CIT0032","doi-asserted-by":"crossref","first-page":"ofw110","DOI":"10.1093\/ofid\/ofw110","article-title":"Noninferior antibiotics: when is \u201cnot bad\u201d \u201cgood enough\u201d","volume":"3","author":"DiNubile","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"2019071803461665300_CIT0033","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1086\/424506","article-title":"A randomized clinical trial to compare fleroxacin-rifampicin with flucloxacillin or vancomycin for the treatment of staphylococcal infection","volume":"39","author":"Schrenzel","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2019071803461665300_CIT0034","doi-asserted-by":"crossref","first-page":"e14170","DOI":"10.1371\/journal.pone.0014170","article-title":"The management of Staphylococcus aureus bacteremia in the United Kingdom and Vietnam: a multi-centre evaluation","volume":"5","author":"Thwaites","year":"2010","journal-title":"PLoS One"},{"key":"2019071803461665300_CIT0035","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s10096-016-2661-5","article-title":"Effectiveness of sequential intravenous-to-oral antibiotic switch therapy in hospitalized patients with gram-positive infection: the SEQUENCE cohort study","volume":"35","author":"Rodriguez-Pardo","year":"2016","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2019071803461665300_CIT0036","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/1469-0691.12632","article-title":"Pan-European early switch\/early discharge opportunities exist for hospitalized patients with methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections","volume":"20","author":"Nathwani","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"2019071803461665300_CIT0037","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1086\/314712","article-title":"Recurrent Staphylococcus aureus bacteremia: pulsed-field gel electrophoresis findings in 29 patients","volume":"179","author":"Fowler","year":"1999","journal-title":"J Infect Dis"},{"key":"2019071803461665300_CIT0038","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jinf.2013.10.015","article-title":"Staphylococcus aureus bloodstream infection: a pooled analysis of five prospective, observational studies","volume":"68","author":"Kaasch","year":"2014","journal-title":"J Infect"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/69\/3\/381\/28949527\/ciy916.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T03:46:35Z","timestamp":1563421595000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/69\/3\/381\/5142664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,23]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,10,23]]},"published-print":{"date-parts":[[2019,7,18]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciy916","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,8,1]]},"published":{"date-parts":[[2018,10,23]]}}}